Ardent Health, Inc. (NYSE:ARDT – Get Free Report) CFO Alfred Lumsdaine purchased 10,000 shares of the firm’s stock in a transaction on Friday, June 5th. The stock was bought at an average cost of $8.81 per share, with a total value of $88,100.00. Following the completion of the purchase, the chief financial officer owned 329,183 shares of the company’s stock, valued at approximately $2,900,102.23. This represents a 3.13% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Ardent Health Price Performance
ARDT remained flat at $8.68 during midday trading on Monday. 445,326 shares of the company’s stock traded hands, compared to its average volume of 421,134. Ardent Health, Inc. has a 12-month low of $7.71 and a 12-month high of $15.48. The company has a quick ratio of 2.00, a current ratio of 2.12 and a debt-to-equity ratio of 0.62. The stock has a market cap of $1.24 billion, a P/E ratio of 9.12, a price-to-earnings-growth ratio of 1.94 and a beta of 0.84. The stock’s 50 day simple moving average is $9.40 and its 200 day simple moving average is $9.11.
Ardent Health (NYSE:ARDT – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.10. Ardent Health had a net margin of 2.09% and a return on equity of 13.85%. The firm had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.58 billion. Ardent Health has set its FY 2026 guidance at 0.900-1.270 EPS. Research analysts predict that Ardent Health, Inc. will post 1.12 EPS for the current year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on ARDT. Wall Street Zen upgraded shares of Ardent Health from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. UBS Group lifted their price objective on shares of Ardent Health from $13.00 to $13.50 and gave the company a “buy” rating in a report on Thursday, May 7th. Royal Bank Of Canada reduced their price objective on shares of Ardent Health from $14.00 to $13.00 and set an “outperform” rating for the company in a report on Monday, March 9th. Zacks Research upgraded shares of Ardent Health from a “strong sell” rating to a “hold” rating in a report on Wednesday, March 25th. Finally, Leerink Partners reduced their price objective on shares of Ardent Health from $16.00 to $15.00 and set an “outperform” rating for the company in a report on Friday, March 6th. Seven investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $14.21.
Get Our Latest Stock Analysis on ARDT
About Ardent Health
Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.
Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.
See Also
- Five stocks we like better than Ardent Health
- A Market Rotation Toward Quality Will Benefit These 3 ETFs
- 3 Multi-Metal Stocks for Income and Long-Term Growth
- Nebius Is Up Nearly 175% This Year—Here’s What’s Driving the Latest Run
- Technology Stocks Just Got Cheaper—Here Are 5 Mega-Caps Worth a Closer Look
Receive News & Ratings for Ardent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardent Health and related companies with MarketBeat.com's FREE daily email newsletter.
